Hansa Biopharma

Hansa Biopharma is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company has pioneered a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, primarily used for desensitizing highly sensitized kidney transplant patients. Hansa's proprietary IgG-cleaving enzyme technology platform supports its drug discovery and development pipeline, targeting transplantation, autoimmune diseases, gene therapy, and new therapies. Headquartered in Lund, Sweden, Hansa operates in Europe and the U.S., aiming to address areas with limited treatment options.

125

3.63

3.60

— Hansa Biopharma
%
Transplantation40% Includes therapies for kidney transplant desensitization.
Autoimmune Diseases25% Therapies targeting autoimmune conditions.
Gene Therapy20% Pre-treatment solutions for gene therapy applications.
New Therapies15% Development of novel treatments for rare conditions.

Hansa Biopharma's customer base primarily includes healthcare providers and institutions involved in organ...

  • Transplant Centersprimary

    Purchase IDEFIRIX for desensitizing kidney transplant patients.

  • Autoimmune Disease Clinicssecondary

    Use therapies for treating complex autoimmune conditions.

  • Gene Therapy Companiesemerging

    Collaborate for pre-treatment solutions to enhance gene therapy.

Hansa Biopharma is headquartered in Lund, Sweden, with significant operations in Europe and the United States...

  • •Headquartered in Lund, Sweden
  • •Operations in Europe and the U.S.
  • •Focus on markets with advanced healthcare systems
  • •Collaborations with leading healthcare institutions

Hansa Biopharma's strategic priorities include advancing its clinical pipeline across core therapeutic areas such as...

01
Pipeline Advancementmedium-term

To address unmet medical needs in core therapeutic areas.

02
Partnership Expansionshort-term

To enhance treatment efficacy in gene therapy.

Hansa Biopharma faces several business and financial risks, including the inherent uncertainties in drug development...

critical

Drug Development Uncertainty

Clinical trials may not achieve expected outcomes.

Materiality
high
high

Sales Fluctuations

Organ allocation systems impact product sales.

Materiality
medium
Revenue Recognition
high
Development Cost Capitalization
medium

Cantargia

CANTA.ST · Health Care

IMMUNIC, INC.

IMUX · Pharmaceutical Preparations

Cue Biopharma, Inc.

CUE · Pharmaceutical Preparations

ADMA BIOLOGICS, INC.

ADMA · Biological Products, (No Diagnostic Substances)

SAB Biotherapeutics, Inc.

SABS · Biological Products, (No Diagnostic Substances)

Regen BioPharma Inc

RGBP · Pharmaceutical Preparations

: 11/08/2026